ARWR

NASDAQ · Biotechnology

Arrowhead Pharmaceuticals In

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$60.77

+4.50 (+8.00%)

As of Mar 25, 9:46 PM ET ·

ARWR News1 articles

Arrowhead Sees Volatility After S&P MidCap 400 Inclusion, Goldman Eyes 2026 Pipeline

Arrowhead Pharmaceuticals shares experienced heightened trading activity and a slight decline following its transition to the S&P MidCap 400 index. Goldman Sachs reiterated a Neutral stance, highlighting pivotal 2026 clinical data and competitive pressures.